PSLT Compared to Prostaglandin Analogue Eye Drops

Status Recruiting

Clinical Trial Summary

This study aims to compare the efficacy of PSLT and the topical use of prostaglandin-like hypotensive eye drops in the treatment of ocular hypertensive or glaucomatous patients in decreasing intraocular pressure and measuring changes in functional, structural and biomechanical parameters evaluated by computerized perimetry and optical coherence tomography (OCT) related to pressure change resulting from treatments

Clinical Trial Description

Patients with a diagnosis of ocular hypertension or bilateral glaucoma, naive or on treatment with up to two classes of hypotensive eye drops will be invited to participate in the study. These patients will have both eyes included in the study. A randomization will be made to allocate one eye to receive treatment with PSLT (treatment group), while the contralateral eye will receive treatment with prostaglandin eye drops (control). Patients will be followed up for 12 months and periodically tonometry, computerized perimetry, water overload test and OCT will be performed. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05241938
Study type	Interventional
Source	Federal University of Rio Grande do Sul
Contact	Helena Pakter, MD, PhD
Phone	+55-51-991226968
Email	Hmpakter@hcpa.edu.br
Status	Recruiting
Phase	N/A
Start date	September 1, 2021
Completion date	December 20, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03284853` - Safety and Efficacy Study of PG324 (Netarsudil/Latanoprost 0.02% / 0.005%) Ophthalmic Solution Compared to GANFORT® Ophthalmic Solution in Open Angle Glaucoma or Ocular Hypertension	Phase 3
Completed	`NCT01157364` - Safety and Efficacy of a New Ophthalmic Formulation of Bimatoprost in Patients With Open Angle Glaucoma and Ocular Hypertension	Phase 1/Phase 2
Not yet recruiting	`NCT06441643` - Next Generation Rocklatan	Phase 2
Recruiting	`NCT02792803` - A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma	Phase 4
Recruiting	`NCT02471105` - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml	Phase 4
Terminated	`NCT02801617` - Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension	Phase 3
Completed	`NCT02558374` - Double-masked Study of Netarsudil (AR-13324) Ophthalmic Solution in Subjects With Glaucoma or Ocular Hypertension	Phase 3
Completed	`NCT02246764` - Study of Netarsudil (AR-13324) Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension	Phase 3
Completed	`NCT02993445` - Effect of Alternate Therapies on Intraocular Pressure in Ocular Hypertension	N/A
Completed	`NCT02628223` - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma	N/A
Completed	`NCT02338362` - Inhaled Corticosteroids: Effect on Intraocular Pressure in Patients With Controlled Glaucoma	Phase 4
Completed	`NCT02390245` - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study	N/A
Completed	`NCT01995136` - Investigation of Intraocular Pressure (IOP) Reduction Efficacy of Travoprost Ophthalmic Solution in Patients With Normal Tension Glaucoma	Phase 4
Completed	`NCT01936389` - A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma	Phase 2
Completed	`NCT02003547` - A Single Centre Study to Evaluate 3 Ophthalmic Formulations in Healthy Subjects	Phase 1
Completed	`NCT01664039` - An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®	Phase 4
Completed	`NCT01693315` - Multiple Dose-escalation Study of AMA0076 in Patients With Ocular Hypertension or Primary Open-angle Glaucoma	Phase 2
Active, not recruiting	`NCT01430923` - Clinical Evaluation of Safety and Efficacy of Refrigeration Free Latanoprost	N/A
Completed	`NCT01340014` - Patient Preference Comparison of AZARGA Versus COSOPT	Phase 4
Completed	`NCT01489670` - Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension	N/A